worldwid
preval
chronic
hepat
c
viru
hcv
infect
estim
approach
million
peopl
current
therapi
reli
upon
combin
pegyl
interferona
ribavirin
poorli
toler
regimen
typic
associ
less
sustain
virolog
respons
rate
infect
genotyp
viru
develop
directact
antivir
agent
treat
hcv
focus
predominantli
inhibitor
viral
enzym
proteas
rnadepend
rna
polymeras
describ
profil
small
molecul
inhibitor
hcv
protein
exhibit
picomolar
halfmaximum
effect
concentr
ec
toward
replicon
express
broad
rang
hcv
genotyp
genotyp
infecti
viru
cell
cultur
phase
clinic
trial
patient
chronic
infect
hcv
administr
singl
dose
associ
log
reduct
mean
viral
load
measur
h
postdos
sustain
addit
h
two
patient
infect
genotyp
viru
genotyp
analysi
sampl
taken
baselin
h
postdos
reveal
major
hcv
variant
observ
substitut
aminoacid
posit
identifi
use
vitro
replicon
system
result
provid
first
clinic
valid
inhibitor
hcv
protein
known
enzymat
function
approach
suppress
viru
replic
offer
potenti
part
therapeut
regimen
base
combin
hcv
inhibitor
design
mechanist
unbias
approach
base
chemic
genet
identifi
chemic
start
point
interf
hcv
replic
differenti
strategi
centr
identif
compound
function
distinct
act
tradit
target
antivir
research
field
proteas
rnadepend
rna
polymeras
use
genotyp
replicon
replic
liver
cell
screen
one
million
compound
bristolmy
squibb
proprietari
collect
high
throughput
mode
use
dual
assay
format
simultan
evalu
replic
relat
flaviviru
bovin
viral
diarrhoea
viru
bvdv
host
cell
cytotox
effici
mean
preliminarili
elimin
compound
without
specif
hcv
activ
inhibitor
triag
evalu
biochem
assay
proteas
helicas
polymeras
addit
screen
panel
unrel
virus
iminothiazolidinon
fig
emerg
weak
importantli
specif
inhibitor
hcv
rna
replic
ec
mm
halfmaximum
cytotox
concentr
cc
mm
resist
map
tyrosin
histidin
substitut
residu
protein
hcv
polyprotein
form
basi
extens
seri
chemic
refin
focus
improv
antivir
potenc
broaden
inhibitori
activ
encompass
hcv
genotyp
optim
oral
bioavail
sustain
pharmacokinet
properti
defin
symmetri
import
contributor
antivir
activ
discoveri
preced
disclosur
structur
inform
see
subsequ
identifi
fig
develop
candid
advanc
clinic
trial
studi
lead
identif
preclin
profil
subject
seri
separ
public
compound
potent
hcv
replic
inhibitor
report
far
mean
ec
valu
pm
genotyp
replicon
respect
data
summar
tabl
display
therapeut
index
cc
ec
least
vitro
inact
toward
panel
rna
dna
virus
ec
valu
greater
mm
confirm
specif
hcv
supplementari
tabl
worldwid
preval
chronic
hepat
c
viru
hcv
infect
estim
approach
million
peopl
current
therapi
reli
upon
combin
pegyl
interferona
ribavirin
poorli
toler
regimen
typic
associ
less
sustain
virolog
respons
rate
infect
genotyp
viru
develop
directact
antivir
agent
treat
hcv
focus
predominantli
inhibitor
viral
enzym
proteas
rnadepend
rna
polymeras
describ
profil
small
molecul
inhibitor
hcv
protein
exhibit
picomolar
halfmaximum
effect
concentr
ec
toward
replicon
express
broad
rang
hcv
genotyp
genotyp
infecti
viru
cell
cultur
phase
clinic
trial
patient
chronic
infect
hcv
administr
singl
dose
associ
log
reduct
mean
viral
load
measur
h
postdos
sustain
addit
h
two
patient
infect
genotyp
viru
genotyp
analysi
sampl
taken
baselin
h
postdos
reveal
major
hcv
variant
observ
substitut
aminoacid
posit
identifi
use
vitro
replicon
system
result
provid
first
clinic
valid
inhibitor
hcv
protein
known
enzymat
function
approach
suppress
viru
replic
offer
potenti
part
therapeut
regimen
base
combin
hcv
inhibitor
design
mechanist
unbias
approach
base
chemic
genet
identifi
chemic
start
point
interf
hcv
replic
differenti
strategi
centr
identif
compound
function
distinct
act
tradit
target
antivir
research
field
proteas
rnadepend
rna
polymeras
use
genotyp
replicon
replic
liver
cell
screen
one
million
compound
bristolmy
squibb
proprietari
collect
high
throughput
mode
use
dual
assay
format
simultan
evalu
replic
relat
flaviviru
bovin
viral
diarrhoea
viru
bvdv
host
cell
cytotox
effici
mean
preliminarili
elimin
compound
without
specif
hcv
activ
inhibitor
triag
evalu
biochem
assay
proteas
helicas
polymeras
addit
screen
panel
unrel
virus
iminothiazolidinon
fig
emerg
weak
importantli
specif
inhibitor
hcv
rna
replic
ec
mm
halfmaximum
cytotox
concentr
cc
mm
resist
map
tyrosin
histidin
substitut
residu
protein
hcv
polyprotein
form
basi
extens
seri
chemic
refin
focus
improv
antivir
potenc
broaden
inhibitori
activ
encompass
hcv
genotyp
optim
oral
bioavail
sustain
pharmacokinet
properti
defin
symmetri
import
contributor
antivir
activ
discoveri
preced
disclosur
structur
inform
see
subsequ
identifi
fig
develop
candid
advanc
clinic
trial
studi
lead
identif
preclin
profil
subject
seri
separ
public
compound
potent
hcv
replic
inhibitor
report
far
mean
ec
valu
pm
genotyp
replicon
respect
data
summar
tabl
display
therapeut
index
cc
ec
least
vitro
inact
toward
panel
rna
dna
virus
ec
valu
greater
mm
confirm
specif
hcv
supplementari
tabl
upon
analysi
determin
inhibitori
activ
map
first
amino
acid
hcv
see
antivir
activ
compound
toward
addit
genotyp
assess
use
replicationcompet
replicon
construct
hybrid
entir
code
region
first
amino
acid
genotyp
replac
correspond
sequenc
parent
replicon
approach
valid
use
genotypespecif
inhibitor
hcv
summar
tabl
demonstr
potent
inhibitori
activ
toward
genotyp
test
ec
valu
rang
pm
combin
studi
display
additivetosynergist
effect
interferona
ribavirin
inhibitor
proteas
nucleosid
alloster
inhibitor
polymeras
indic
potenti
molecul
candid
combin
therapi
hcv
therapeut
agent
data
summar
tabl
supplementari
tabl
significantli
potent
inhibitor
genotyp
infecti
viru
replic
cell
cultur
ec
pm
assay
consid
biolog
relev
vitro
cell
cultur
system
addit
display
similar
potenc
hela
cell
supplementari
tabl
demonstr
function
inhibit
highli
conserv
differ
cellular
environ
character
resist
profil
genotyp
replicon
cell
maintain
presenc
drug
concentr
time
respect
ec
valu
direct
sequenc
individu
clone
cell
reveal
multipl
chang
first
amino
acid
individu
introduc
wildtyp
replicon
background
display
resist
phenotyp
tabl
show
result
contribut
substitut
resist
transient
replic
assay
use
ensur
observ
resist
phenotyp
caus
inhibitorinduc
substitut
genotyp
identifi
major
resist
variant
wherea
chang
observ
residu
genotyp
addit
substitut
residu
gener
substitut
genotyp
confer
modest
effect
potenc
wherea
substitut
genotyp
associ
much
higher
level
resist
replicon
system
resist
variant
inhibit
vitro
ec
approxim
nm
plasma
concentr
shown
readili
achiev
human
oral
dose
see
indic
singlepoint
substitut
suppress
vivo
notabl
mani
resist
variant
display
reduc
fit
vitro
none
record
major
speci
hcv
sequenc
databas
suggest
natur
select
prevent
domin
advantag
vivo
cyclosporin
structur
relat
compound
inhibit
hcv
replic
vitro
vivo
resist
map
part
domain
ii
iii
assess
potenti
crossresist
sensit
inhibit
cyclosporin
genotyp
replicon
express
rang
substitut
confer
resist
examin
cyclosporin
inhibit
significantli
affect
substitut
studi
ec
valu
compar
observ
wildtyp
genotyp
replicon
supplementari
tabl
confirm
inhibitor
bind
viral
protein
prepar
biotintag
deriv
natur
configur
prolin
stereocentr
diastereom
fig
compound
inhibit
subgenom
viral
rna
replic
genotyp
replicon
ec
nm
inact
toward
replicon
ec
mm
wherea
diastereom
use
control
inact
vitro
ec
mm
exposur
activ
inhibitor
replicon
lysat
pass
streptavidin
agaros
bead
separ
sdspolyacrylamid
gel
electrophoresi
probe
antibodi
specif
hcv
parallel
experi
use
inact
diastereom
serv
control
could
pull
effici
activ
inhibitor
inact
compound
fig
detect
pulldown
experi
suggest
select
bind
similar
experi
conduct
replicon
express
bvdv
rna
compound
fail
bind
bvdv
hcv
aminoacid
zincbind
phosphoprotein
play
critic
import
enigmat
role
viru
life
cycl
substitut
confer
resist
map
domain
protein
incorpor
amphipath
amino
n
termin
ahelix
residu
thought
anchor
protein
membran
solidst
structur
fragment
domain
residu
hcv
reveal
dimer
complex
pattern
interfaci
recognit
anticip
oligomer
form
protein
postul
sequest
rna
within
replic
complex
uniqu
palindrom
topolog
complement
dimer
structur
protein
locat
resist
substitut
suggest
compound
bind
across
dimer
interfac
proxim
n
terminu
domain
protein
membran
face
opposit
put
rna
bind
domain
specul
may
interfer
precis
dimer
associ
effect
subtl
structur
distort
directli
alloster
interfer
protein
function
circumst
exquisit
inhibitori
potenc
exhibit
vitro
may
relat
disrupt
function
limit
number
dimer
compromis
activ
oligomer
complex
howev
although
hypothesi
allow
amplif
inhibitori
effect
altern
explan
reli
inhibit
two
activ
interact
synergist
studi
requir
defin
exact
mode
action
fulli
convers
compound
use
tool
studi
aspect
hcv
function
viral
replic
investig
may
aid
compound
vitro
profil
similar
restrict
genotyp
inhibit
exhibit
signific
effect
extens
batteri
vitro
receptor
bind
enzymat
assay
design
assess
promiscu
despit
molecular
mass
dalton
compound
oral
bioavail
four
preclin
speci
plasma
level
readili
achiev
surpass
vitro
ec
distribut
effect
liver
random
doubleblind
placebocontrol
singl
ascendingdos
studi
administ
six
dose
level
healthi
nonhcvinfect
subject
rang
mg
oral
solut
compound
safe
well
toler
mg
letter
clinic
relev
advers
effect
oral
administr
readili
absorb
doseproport
exposur
studi
dose
rang
subject
drug
concentr
greater
proteinbindingadjust
ec
genotyp
measur
replicon
assay
beyond
h
postdos
fig
protein
bindingadjust
ec
figur
deriv
analysi
effect
addit
human
serum
antivir
activ
replicon
presenc
human
serum
ec
pm
ng
ml
genotyp
replicon
pm
ng
ml
genotyop
replicon
random
doubleblind
placebocontrol
singl
ascendingdos
studi
administ
subject
genotyp
chronic
hcv
dose
mg
oral
solut
subject
infect
hcv
genotyp
except
two
subject
mg
three
subject
mg
infect
genotyp
safe
well
toler
hcvinfect
subject
singl
oral
dose
mg
specif
death
seriou
advers
event
discontinu
due
advers
event
clinic
relev
advers
effect
headach
frequent
advers
event
report
four
subject
administr
hcvinfect
subject
mean
plasma
elimin
halflif
rang
h
plasma
drug
level
similar
nonhcvinfect
subject
singl
oral
dose
mg
subject
plasma
concentr
tenfold
protein
bindingadjust
ec
hcv
genotyp
suggest
possibl
daili
administr
plasma
hcv
rna
level
measur
day
administr
mean
declin
time
administr
h
postdos
shown
fig
singl
milligram
dose
produc
mean
log
reduct
rang
log
hcv
viral
load
measur
h
drug
administr
mg
dose
produc
greater
antivir
effect
mean
plasma
viral
rna
fall
log
rang
log
log
rang
log
respect
h
postdos
moreov
mg
dose
result
mean
maxim
hcv
rna
declin
log
rang
log
prolong
antivir
respons
observ
two
subject
infect
genotyp
viru
hcv
rna
measur
reach
lower
limit
quantif
less
iu
ml
one
subject
iu
ml
measur
hour
genotyp
analysi
sampl
taken
baselin
hour
postdos
reveal
gener
mark
reduct
viral
load
requir
detect
major
hcv
variant
substitut
observ
aminoacid
posit
identifi
use
vitro
replicon
system
supplementari
tabl
genotyp
genotyp
result
suggest
use
replicon
system
assess
resist
respons
inhibitor
pressur
vivo
followup
sampl
avail
one
subject
reveal
hcv
rna
return
near
baselin
howev
genotyp
analysi
perform
sampl
would
anticip
base
vitro
replicon
potenc
greater
sustain
declin
hcv
rna
observ
subject
infect
genotyp
mean
log
reduct
rang
log
mean
log
reduct
rang
log
hcv
viral
load
measur
h
mg
dose
respect
subject
infect
genotyp
mean
log
reduct
rang
log
mean
log
reduct
rang
log
mean
log
reduct
rang
log
hcv
viral
load
measur
h
mg
dose
respect
mean
rate
declin
subject
receiv
mg
dose
similar
h
dose
mean
declin
greater
sustain
subject
receiv
mg
subject
receiv
mg
lower
mean
declin
hcv
rna
subject
treat
mg
fig
howev
multipledos
studi
need
defin
optim
dose
rang
maxim
antivir
effect
beyond
first
phase
viral
declin
relationship
maximum
declin
baselin
hcv
rna
drug
pharmacokinet
exposur
explor
use
pearson
correl
coeffici
estim
pearson
correl
coeffici
suggest
maximum
declin
log
hcv
rna
log
pharmacokinet
exposur
c
max
auc
auc
inf
posit
correl
maximum
declin
log
hcv
rna
increas
exposur
individu
infect
hcv
consider
risk
develop
liver
cirrhosi
endstag
liver
diseas
hepatocellular
carcinoma
current
standard
care
treatment
hcv
infect
combin
weekli
subcutan
inject
pegyl
interferona
conjunct
ribavirin
administ
oral
twice
day
period
rang
week
depend
genotyp
howev
side
effect
associ
therapeut
regimen
impos
signific
physiolog
psycholog
burden
patient
moreov
sustain
virolog
respons
rate
infect
genotyp
typic
less
ref
directact
hcv
antivir
drug
candid
current
report
latestag
clinic
develop
inhibitor
proteas
polymeras
tradit
antivir
target
although
compound
current
develop
addon
therapi
standard
care
consider
anticip
combin
directact
agent
requir
least
two
mechanist
distinct
inhibitor
suppress
emerg
resist
viru
preliminari
vitro
clinic
profil
inhibitor
describ
paper
make
potenti
valuabl
compon
interferonfre
treatment
regimen
figur
activ
inhibitor
bind
genotyp
hcv
wherea
inact
stereoisom
genotyp
replicon
cell
expos
either
approxim
h
cell
lyse
portion
supernat
set
asid
serv
input
control
immunoblot
analysi
lane
remaind
mix
streptavidinagaros
bead
incub
sever
hour
bound
protein
detect
immunoblot
primari
antibodi
direct
hcv
lane
depict
result
experi
activ
inhibitor
compound
wherea
lane
depict
result
inact
stereoisom
result
provid
clinic
valid
first
new
class
hcv
inhibitor
target
viral
protein
known
enzymat
function
yet
poorli
understood
role
viral
replic
strategi
use
identifi
lead
hcv
inhibitor
optim
molecul
clinic
candid
offer
contemporari
demonstr
effect
approach
drug
discoveri
base
chemic
genet
inde
methodolog
uniqu
applic
target
similar
hcv
precis
function
enigmat
develop
biochem
assay
could
neither
anticip
feasibl
specif
inhibitor
hcv
exhibit
spectrum
genotyp
inhibit
vitro
potenc
efficaci
potenc
singl
oral
dose
chronic
hcvinfect
subject
collect
individu
unpreced
achiev
high
potenc
select
nonmammalian
target
tradit
goal
antivir
medicin
chemistri
past
translat
wider
therapeut
index
clinic
although
preliminari
data
indic
inhibitor
hcv
offer
consider
promis
treatment
hcv
infect
vitro
data
demonstr
addit
synergist
interact
known
hcv
inhibitor
doubleblind
placebocontrol
sequenti
singl
ascendingdos
studi
six
subject
random
within
dose
panel
mg
drug
placebo
ratio
placebo
administ
fast
state
owe
dose
error
six
subject
receiv
mg
panel
one
subject
mg
panel
withdrew
studi
h
administr
studi
drug
nondrugrel
reason
hcv
rna
data
subject
includ
subject
withdrew
mg
n
mg
n
mg
n
mg
n
mg
n
mg
n
pba
ec
replicon
ng
ml
genotyp
pba
ec
replicon
ng
ml
genotyp
suggest
combin
either
current
standard
care
ultim
emerg
inhibitor
hcv
part
cocktail
directact
antivir
agent
may
lead
therapeut
regimen
better
toler
improv
clinic
outcom
vitro
hcv
replicon
system
construct
isol
hcv
replicon
includ
hybrid
replicon
genotyp
coverag
replicon
assay
describ
previous
elabor
supplementari
inform
genotyp
replicon
substitut
gene
substitut
gene
use
adapt
substitut
effici
replicon
replic
genotyp
replicon
substitut
gene
use
adapt
mutat
hcvinfect
clinic
studi
popul
total
subject
receiv
treatment
two
subject
receiv
placebo
subject
select
studi
includ
men
women
age
year
inclus
chronic
infect
hcv
genotyp
treatment
naiv
treatment
nonrespond
defin
subject
receiv
current
standard
care
interferon
andor
ribavirin
continu
detect
hcv
rna
level
includ
relaps
subject
attain
log
declin
hcv
rna
level
week
stop
treatment
treatmentintoler
subject
defin
subject
unabl
toler
toxic
associ
interferon
andor
ribavirin
receiv
anoth
replic
cofactor
inhibitor
coinfect
human
immunodefici
viru
hepat
b
viru
hcv
genotyp
elig
subject
also
hcv
rna
viral
load
least
iu
ml
document
fibrosur
score
aspart
aminotransferas
platelet
ratio
index
bodi
mass
index
kg
inclus
subject
sign
inform
consent
form
screen
determin
elig
base
medic
histori
physic
examin
measur
vital
sign
electrocardiogram
clinic
laboratori
measur
includ
serolog
full
method
associ
refer
avail
onlin
version
paper
wwwnaturecomnatur
